Search results for " Fabs"
Article
Single-Domain Antibodies for Brain Targeting
Hence, the reduction of the Fabs to a monomeric domain unit, as VH or VL, should be, theoretically, more effective in the recognition of the associated antigen. Thus, dissecting IgGs initially through…
Article
Modeling the Degradation of mAb Therapeutics
Modeling the Degradation of mAb Therapeutics
Kinetic models can be used to study aggregation and fragmentation to help ensure stability.
By Anurag S. Rathore, Rohit Bansal
…
Article
Antibody Production in Microbial Hosts
The authors review the status of expression of antibodies in microbial hosts and present the recent advances in the production of aglycosylated antibodies in bacteria.
By Anurag S. Rathore, Jyot…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Cimzia and Lucentis are two recently approved Fabs produced in E. coli (29) and although no scFv has yet received regulatory approved, there are a large number of both types of Ab fragments in clinica…
Article
Protein L affinity resin is ready to move to manufacturing
Although protein L affinity resins have been available for more than a decade, insufficient binding capacities and alkaline stability challenges have limited their use in productive manufactur…
Article
Real-Time Characterization of Biotherapeutics and Comparability of Biosimilars
Real-Time Characterization of Biotherapeutics and Comparability of Biosimilars
A major advantage of SPR-based analysis is its ability to estimate the association and dissociation rate constants, an …
Article
N-Glycan Analysis of Biotherapeutic Proteins
This article summarizes the approaches, challenges, and future perspectives for the characterization of N-glycans in biopharmaceutical products.
By Aled Jones
Protein glycosylation, the addi…
Article
Cost Considerations Drive Lean Technology in Biopharmaceutical Manufacturing
By Catherine Shaffer
Four biosimilars have been approved for the market by FDA as of February 2017, and more are in the pipeline. Now that biosimilars are here to stay, manufacturers are devel…
Article
Resolving a bottleneck in screening and characterization of recombinant antibody fragments using Biacore 4000
Antibodies and their derivatives are increasingly important as biotherapeutics, precision diagnostics, and essential tools for biological research. Techniques to screen and characterize large number…
Article
Chromatography processes for the diversified therapeutic antibody pipeline
The diversity of antibody variants in today’s pipeline presents unique challenges for purification and we see molecules such as bsAbs, Fabs, dAbs, and others. Conventional chromatography protocols, …